Xin Lang Cai Jing·2025-11-18 05:41Group 1 - The core issue involves investor claims against Aolian Electronics (300585) due to false statements, with ongoing legal actions being pursued by attorney Xu Feng [1][2] - Aolian Electronics received an administrative penalty from the China Securities Regulatory Commission (CSRC) for misleading statements regarding its performance in the perovskite sector, leading to a significant stock price drop of 29.92% over two trading days [1] - The stock price decline of Aolian Electronics was notably higher than the broader market, with a deviation of 28.76 percentage points from the ChiNext Index during the same period [1] Group 2 - Attorney Xu Feng indicates that investors who purchased Aolian Electronics shares between December 12, 2022, and February 21, 2023, may still initiate claims, as the statute of limitations is nearing its end [2] - The law firm is also handling claims for investors of Puli Pharmaceutical (300630), with some cases already in court and awaiting further court arrangements [2] - Puli Pharmaceutical was found to have inflated its revenue and profits through fictitious sales from 2021 to 2022, with significant overstatements in both years [3] Group 3 - Investors who bought Puli Pharmaceutical shares between April 26, 2022, and April 17, 2024, are also eligible to file claims, as per attorney Xu Feng's guidance [4] - The law firm has a history of successfully representing investors in securities fraud cases, with numerous claims currently in progress [4]